<DOC>
<DOCNO>EP-0635495</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Benzospiroalkene derivates, process for their preparation and pharmaceutical compositions containing them
</INVENTION-TITLE>
<CLASSIFICATIONS>C07D49500	A61K31429	A61K31428	C07D49810	A61K31429	A61P912	C07D49510	A61K31425	A61P2520	C07D26300	A61P904	A61P2300	C07D49100	A61P900	A61P4300	A61K31415	A61K314162	A61K314162	A61K31424	C07D49300	A61K314184	C07D49310	C07D491107	C07D49800	A61K314164	C07D51310	A61P2502	A61K3142	A61P4300	C07D23502	A61P2500	C07D51300	A61K31428	A61P2300	A61K31423	C07D26352	C07D27760	A61P2302	A61K31423	C07D23500	A61K3142	A61K31425	A61K31415	A61K314188	A61P914	A61P900	A61P2530	C07D27700	A61K31424	A61P2504	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07D	A61K	A61K	C07D	A61K	A61P	C07D	A61K	A61P	C07D	A61P	A61P	C07D	A61P	A61P	A61K	A61K	A61K	A61K	C07D	A61K	C07D	C07D	C07D	A61K	C07D	A61P	A61K	A61P	C07D	A61P	C07D	A61K	A61P	A61K	C07D	C07D	A61P	A61K	C07D	A61K	A61K	A61K	A61K	A61P	A61P	A61P	C07D	A61K	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07D495	A61K31	A61K31	C07D498	A61K31	A61P9	C07D495	A61K31	A61P25	C07D263	A61P9	A61P23	C07D491	A61P9	A61P43	A61K31	A61K31	A61K31	A61K31	C07D493	A61K31	C07D493	C07D491	C07D498	A61K31	C07D513	A61P25	A61K31	A61P43	C07D235	A61P25	C07D513	A61K31	A61P23	A61K31	C07D263	C07D277	A61P23	A61K31	C07D235	A61K31	A61K31	A61K31	A61K31	A61P9	A61P9	A61P25	C07D277	A61K31	A61P25	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of formula (I): 
<
IMAGE
>
  in which:   - X represents -CH2-, -(CH2)2-, -CH=CH-, -O-CH2-, -S-CH2-, -SO-CH2- or -SO2-CH2-,   - Y represents an oxygen or sulphur atom or a group -NR5-, - R represents a halogen atom, a linear or branched (C1-C6)alkyl group (substituted or unsubstituted), a hydroxyl group or a linear or branched (C1-C6)alkoxy group, - R2 represents a hydrogen or halogen atom, a linear or branched (C1-C6)alkyl group (substituted or unsubstituted), a hydroxyl group, a linear or branched (C1-C6)alkoxy group or a linear or branched (C1-C6)alkylthio group, - R3 represents a hydrogen or halogen atom, a linear or branched (C1-C6)alkyl group (substituted or unsubstituted), a hydroxyl group, a linear or branched (C1-C6)alkoxy group or a linear or branched (C1-C6)alkylthio group, - R4 represents a hydrogen atom or an amino group (substituted or unsubstituted), - R5 represents a hydrogen atom or a linear or branched (C1-C6)alkyl group, or else -R1 and R2 form, together with the carbon atoms which carry them, a benzene ring, provided that, in this case, X represents -CH2- or -(CH2)2-, their isomers and their addition salts with a pharmaceutically acceptable acid. Medicaments.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
Compounds of formula (I) :


wherein :

- X
represents -CH
2
-, -( CH
2
)
2
-, -CH=CH-, -O-CH
2
-, -S-CH
2
-, -SO-CH
2
- or -SO
2
-CH
2
-,
- Y
represents an oxygen atom, a sulphur atom or an -NR
5
- group,
- R
1
represents a halogen atom, a linear or branched (C
1
-C
6
)-alkyl group (unsubstituted
or substituted by one or more halogen atoms), a hydroxy group or a linear or

branched (C
1
-C
6
)-alkoxy group,
- R
2
represents a hydrogen atom, a halogen atom, a linear or branched (C
1
-C
6
)-alkyl
group (unsubstituted or substituted by one or more halogen atoms), a hydroxy

group, a linear or branched (C
1
-C
6
)-alkoxy group or a linear or branched (C
1
-C
6
)-alkylthio
group,
- R
3
represents a hydrogen atom, a halogen atom, a linear or branched (C
1
-C
6
)-alkyl
group (unsubstituted or substituted by one or more halogen atoms), a hydroxy

group, a linear or branched (C
1
-C
6
)-alkoxy group or a linear or branched (C
1
-C
6
)-alkylthio
group,
- R
4
represents a hydrogen atom or an amino group (unsubstituted or substituted by one
or two linear or branched (C
1
-C
6
)-alkyl groups),
- R
5
represents a hydrogen atom or a linear or branched (C
1
-C
6
)-alkyl group,

or

R
1
 and R
2
, together with the carbon atoms carrying them, form a benzene ring,
with the proviso that in that case X represents -CH
2
- or -(CH
2
)
2
-,

their isomers and also the addition salts thereof with a pharmaceutically acceptable acid. 
Compounds of formula (I) according to claim 1 wherein X represents -(CH
2
)
2
-, their
isomers, and also the addition salts thereof with a pharmaceutically acceptable acid.
Compounds of formula (I) according to claim 1 wherein Y represents -NH-, their
isomers, and also the addition salts thereof with a pharmaceutically acceptable acid.
Compounds of formula (I) according to claim 1 wherein Y represents an oxygen atom,
their isomers, and also the addition salts thereof with a pharmaceutically acceptable acid.
Compounds of formula (I) according to claim 1 wherein R
2
 and R
3
 simultaneously
represent a hydrogen atom, their isomers, and also the addition salts thereof with a

pharmaceutically acceptable acid.
Compounds of formula (I) according to claim 1 wherein R
4
 represents a hydrogen
atom, their isomers, and also the addition salts thereof with a pharmaceutically acceptable

acid.
Compounds of formula (I) according to claim 1 wherein R
4
 represents an amino group,
their isomers, and also addition salts thereof with a pharmaceutically acceptable acid.
Compound of formula (I) according to claim 1 which is spiro[5-(1,3-diazacyclopent-1-ene)
: 2'-(8'-chloro-1',2',3',4'-tetrahydronaphthalene)]
, its isomers, and also the addition
salts thereof with a pharmaceutically acceptable acid.
Compound of formula (I) according to claim 1 which is spiro[4-(1-oxa-2-amino-3-azacyclopent-2-ene)
: 2'-(8'-chloro-1',2',3',4'-tetrahydronaphthalene)]
, its isomers, and also
the addition salts thereof with a pharmaceutically acceptable acid.
Process for the preparation of compounds of formula (I) according to claim 1 wherein
Y represents an -NR
5
- group, characterised in that there is used as starting material a
compound of formula (II) :



wherein X, R
1
, R
2
 and R
3
 are as defined for formula (I),
 
which is reacted :


either
 with benzylamine in the presence of para-toluenesulphonic acid to yield a
compound of formula (III) :



wherein X, R
1
, R
2
 and R
3
 are as defined for formula (I),

which is reacted in an inert atmosphere with trimethylsilyl cyanide in the presence of zinc
iodide

to yield a compound of formula (IV) :


wherein X, R
1
, R
2
 and R
3
 are as defined for formula (I),

which is reduced with lithium aluminium hydride and then by catalytic hydrogenation to
yield a compound of formula (V)



wherein X, R
1
, R
2
 and R
3
 are as defined for formula (I),
or
 with potassium cyanide in the presence of ammonium chloride in an inert medium, or
with sodium cyanide in acid medium, or with trimethylsilyl cyanide in the presence of

zinc iodide then with a saturated solution of ammonia in alcohol,
 
to yield a compound of formula (VI) :



wherein X, R
1
, R
2
 and R
3
 are as defined for formula (I),

which is reduced with lithium aluminium hydride to yield a compound (V) described
above,

which compound of formula (V)

is reacted with formamidine in alcoholic medium, an alkyl formate or with a cyanogen
halide (followed, depending on the nature of the desired compound of formula (I), by an

alkylation reaction using an alkyl halide),

to yield a compound of formula (I/a) :


wherein X, R
1
, R
2
, R
3
, R
4
 and R
5
 are as defined for formula (I), a particular case of
compounds of formula (I),

which compound of formula (I/a)

is purified, if necessary, according to a conventional purification technique,

is separated, if desired, into its isomers according to a conventional purification technique,
and is optionally converted into addition salts thereof with a pharmaceutically acceptable

acid.
Process for the preparation of a compound of formula (I) according to claim 1 wherein
Y represents an oxygen atom or a sulphur atom, characterised in that there is used as

starting material a compound of formula (VI) according to claim 10,

which is reacted with formic acid in an anhydrous medium saturated with hydrochloric
acid, to yield a compound of formula (VII) : 



wherein R
1
, R
2
, R
3
 and X are as defined for formula (I),

which is converted in concentrated hydrochloric acid medium into the corresponding acid
of formula (VIII) :



wherein R
1
, R
2
, R
3
 and X are as defined for formula (I),

which is subjected to reduction with lithium aluminium hydride in inert medium
to yield a compound of formula (IXa) :



wherein R
1
, R
2
, R
3
 and X are as defined for formula (I),

which compound of formula (IXa) is converted, depending on the nature of the desired
compounds of formula (I), into the corresponding tosylate using para-toluenesulphonic

acid and is then reacted with thiourea or thioacetic acid

to yield, after hydrolysis, a compound of formula (IXb) :


wherein R
1
, R
2
, R
3
 and X are as defined for formula (I),
 
which compound of formula (IXa) or (IXb) is reacted with formamidine in alcoholic

medium, an alkyl formate or with a cyanogen halide (followed, depending on the nature of
the desired compound of formula (I), by an alkylation reaction using an alkyl halide),

to yield a compound of formula (I/b)


wherein R
1
, R
2
, R
3
, R
4
 and X are as defined above and Y' represents an oxygen atom or a
sulphur atom, a particular case of compounds of formula (I),

which compound of formula (I/b)

is purified, if necessary, according to a conventional purification technique,

is separated, if desired, into its isomers according to a conventional purification technique,
and is optionally converted into addition salts thereof with a pharmaceutically acceptable

acid.
Pharmaceutical compositions comprising as active ingredient at least one compound
according to any one of claims 1 to 9, alone or in combination with one or more

pharmaceutically acceptable, inert, non-toxic excipients or carriers.
Pharmaceutical compositions according to claim 12 containing at least one active
ingredient according to any one of claims 1 to 9 employed as an Î±
2
-adrenergic agonist, as
an anaesthetic, analgesic, hypotensive, sedative, vasoconstrictor or decongestant or to

relieve the symptoms of opiate withdrawal.
</CLAIMS>
</TEXT>
</DOC>
